HARP News and Press, Harpoon Therapeutics Inc. From 08/03/19

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...

SOUTH SAN FRANCISCO, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will present at tw...

WATERTOWN, Mass., June 20, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced the appoi...

Cyclacel Pharmaceuticals (NASDAQ: CYCC ) initiated with Buy rating and $8 (1173% upside) price target at Roth Capital Partners. More news on: Cyclacel Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Fate Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...

Harpoon Therapeutics (NASDAQ: HARP ): Q1 GAAP EPS of -$0.92 misses by $0.50 . More news on: Harpoon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Continued enrollment of Phase 1 trial for HPN424, Harpoon’s lead TriTAC product candidate in development for the treatment of prostate cancer Net proceeds of approximately $71 million from completion of initial public offering in February SOUTH SAN FRANCISCO, Calif., May 09, 201...

Novartis ( NVS ): The stock has been tumbling after the company announced interim data from the Phase 2 STR1VE trial of Zolgensma/AVXS-101 in spinal muscular atrophy ( SMA ) Type 1. While it's true that prolonged event-free survival and rapid increase in CHOP-INTEND scores were encouragi...

Harpoon Therapeutics (NASDAQ: HARP ) has dosed first patient with HPN536 in a Phase 1/2a clinical trial initially focused on ovarian cancer. More news on: Harpoon Therapeutics, Inc., Healthcare stocks news, Read more ...

HPN536 is the second TriTAC T cell engager to enter clinical development from the Harpoon pipeline Trial initiated at Sarah Cannon Research Institute in Nashville, Tenn. - a leading drug development organization SOUTH SAN FRANCISCO, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Harpoo...

The first quarter of 2019 was robust with activity for the biotechnology industry thanks to merger and acquisitions (M&A) in addition to initial public offerings (IPOs).  Looking back to the end of last year, the biotech sector took a significant hit in terms of stock performance, ...